Axa S.A. Clovis Oncology, Inc. Transaction History

Axa S.A.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.63 - $2.96 $12,978 - $60,976	-20,600 Closed	0 $0
Q1 2022 Feb 14, 2023	BUY	$1.43 - $3.14 $29,458 - $64,684	20,600 New	20,600 $41,000
Q1 2022 May 13, 2022	SELL	$1.43 - $3.14 $544,401 - $1.2 Million	-380,700 Reduced 94.87%	20,600 $42,000
Q4 2021 Feb 14, 2022	BUY	$2.7 - $4.76 $1.08 Million - $1.91 Million	401,300 New	401,300 $1.09 Million
Q1 2021 May 14, 2021	SELL	$4.81 - $10.34 $1.64 Million - $3.53 Million	-341,100 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$4.13 - $6.41 $19,613 - $30,441	4,749 Added 1.41%	341,100 $1.64 Million
Q3 2020 Nov 13, 2020	SELL	$4.82 - $7.72 $60,486 - $96,878	-12,549 Reduced 3.6%	336,351 $1.96 Million
Q2 2020 Aug 14, 2020	BUY	$5.69 - $9.69 $1.99 Million - $3.38 Million	348,900 New	348,900 $2.36 Million
Q1 2018 May 14, 2018	SELL	$50.12 - $67.72 $786,884 - $1.06 Million	-15,700 Closed	0 $0
Q4 2017 Feb 13, 2018	SELL	$57.69 - $84.58 $1.14 Million - $1.67 Million	-19,700 Reduced 55.65%	15,700 $1.07 Million
Q3 2017 Nov 13, 2017	BUY	$67.17 - $84.81 $2.38 Million - $3 Million	35,400	35,400 $2.92 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.